Peptide and compounding law · Updated
Advertising peptides and compounded drugs: the rules for clinics and telehealth companies
Ads for compounded drugs answer to three sets of rules. Federal law has treated a compounded drug as misbranded since 2013 "If the advertising or promotion of a compounded drug is false or misleading in any particular" (21 U.S.C. 352(bb)), and the FDA has used that provision against telehealth companies, clinics and med spas that do not compound anything themselves. Since September 2025 its warning letters have objected to calling a compounded drug generic, "the same" as an approved drug or made with the "same active ingredient", to calling the drug or its pharmacy "FDA-approved", and to putting the seller's name alone on the vial label. The FTC requires competent and reliable scientific evidence for health claims and bars fake and paid-for reviews. The North Carolina Medical Board treats deceptive, false or misleading advertising by its licensees as unprofessional conduct. A "research use only" label changes none of this when a product is marketed for people.
| Claim or practice | Rule that reaches it | Where the regulator said so |
|---|---|---|
| "Generic Wegovy" or "generic semaglutide" | FDA: false or misleading labeling and promotion, 21 U.S.C. 352(a) and (bb). "Compounded drugs are also not the same as generic drugs, which are FDA-approved" | FDA, March 3, 2026; warning letter of Sept. 9, 2025 |
| "Same active ingredient as Ozempic and Wegovy" | 352(a) and (bb): the claims "imply that your products are the same as an FDA-approved product when they are not" | Warning letters of Sept. 9, 2025 and Feb. 20, 2026; FDA, Feb. 6, 2026 |
| "Similar to Mounjaro and Zepbound" | 352(a) and (bb) | Warning letter of Sept. 9, 2025 |
| "FDA-approved compounded medications" | 352(a) and (bb): "Compounded drug products are not FDA-approved" | Warning letter of Oct. 30, 2026 |
| "Our compounding pharmacies are all FDA approved" | 352(a) and (bb): the Act has no "'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities" | Warning letter of June 8, 2026; FDA telehealth page (June 15, 2026) |
| "Clinically proven" | FDA: 352(a) and (bb). FTC: health claims need "competent and reliable scientific evidence" | Warning letter of Sept. 9, 2025; FTC guidance |
| The clinic's or platform's name alone on the vial label | A name "without qualification" represents "the sole manufacturer" (21 CFR 201.1(h)(2)) | Warning letters of June 8, 2026 (a med spa) and Oct. 30, 2026 |
| "American made" or "farm-to-table" drugs | 352(a) and (bb): such claims can "conceal the true origin" of the products | Warning letter of Oct. 30, 2026 |
| A headline claim with a "may not be FDA-approved" footer | FDA: disclaimers "do not cure the misleading" overall impression. FTC: a disclosure "must alter the net impression" | Warning letter of Oct. 30, 2026; 16 CFR 255.2(b) |
| "Members lose 53 pounds on average" | FTC Act Sections 5 and 12; typical-results claims need "competent and reliable evidence". NC Medical Board: avoid "unjustified medical expectations" | FTC, July 14, 2025 (settled) |
| Before-and-after photos of people who are not patients | FTC (alleged in the same case). NC Medical Board: photos "should be of the licensee's own patients and demonstrate realistic outcomes" | NCMB (amended July 2026) |
| Reviews or testimonials written by staff or family | 16 CFR 465.2 and 465.5; undisclosed material connections, 16 CFR 255.5. NC Medical Board: no "false patient testimonials" | FTC rule effective Oct. 21, 2024 |
| A gift card or refund for a five-star review, or for removing a bad one | 16 CFR 465.4; 16 CFR 255.2(d) | FTC order against a GLP-1 telehealth firm, Dec. 3, 2025 (settled) |
| An advertised monthly price that leaves out the drug | FTC Act Section 5 | FTC, July 14, 2025 (settled) |
| Peptides sold "for research use only" next to dosing tools | Unapproved new drugs; intended use is judged from the whole website (21 CFR 201.128) | Warning letter of Aug. 24, 2026 (a Cornelius, NC seller) |
| "Now legal" or "FDA-allowed" for a peptide in HHS's draft policy | In our reading, the same 352(a) and (bb) problem: enforcement discretion is not approval | 91 FR 68526: compounded drugs "are not FDA-approved" |
| Regulator or platform | What it reaches | Main rule | Consequence |
|---|---|---|---|
| FDA | Labeling (labels and matter "accompanying" the drug) and, for compounded drugs, any advertising or promotion | 21 U.S.C. 352(a), (bb); 321(m), (n) | Warning letters asking for a response in 15 working days; the drug is misbranded |
| FTC | "all forms of advertising", including social media, influencers and messages through practitioners | 15 U.S.C. 45, 52, 55; 16 CFR 255 and 465 | Orders; for knowing violations of a rule such as the review rule, civil penalties of up to $53,088 per violation (16 CFR 1.98) |
| NC Medical Board | Advertising "disseminated by, or at the direction of, a licensee" | Advertising and Publicity (amended July 2026) | "unprofessional conduct under the Medical Practice Act" |
| Google, Meta (platform rules, not law) | Ads on their services | LegitScript certification for telehealth and online pharmacies in the US; Google's unapproved-substances rules | Ads refused or accounts restricted |
The FDA rule for compounded-drug advertising
Two provisions of the Food, Drug, and Cosmetic Act do most of the work. A drug is misbranded "If its labeling is false or misleading in any particular" (21 U.S.C. 352(a)), and, since the Drug Quality and Security Act of 2013, "If the advertising or promotion of a compounded drug is false or misleading in any particular" (352(bb)) (uscode.house.gov). "Labeling" covers written, printed or graphic matter on the drug or its containers or "accompanying such article" (321(m)), and whether labeling or advertising is misleading takes account of what it says and of "the extent to which the labeling or advertising fails to reveal facts material in the light of such representations" (321(n)) (uscode.house.gov).
Compounded drugs used to carry a different rule: before 2013, a pharmacy could compound under section 503A only if it did "not advertise or promote the compounding of any particular drug, class of drug, or type of drug" (the former 353a(c), struck by Pub. L. 113-54) (uscode.house.gov). Advertising is now allowed, and 352(bb) polices it. The 503A exemptions do not include 352(a) or 352(bb), so a compounded drug's labeling and promotion are fully subject to both.
In our reading, 352(bb) reaches more than the pharmacy. It speaks of "the advertising or promotion of a compounded drug" without saying who advertises, and the FDA has sent letters under it to telehealth platforms, professional practices and med spas that buy compounded drugs rather than make them. A clinic's website, social posts, intake pages and labels are within it.
What the FDA has objected to since September 2025
The FDA's warning-letter index shows four rounds aimed at telehealth sellers of compounded GLP-1 drugs: 58 letters dated September 9, 2025, 30 dated February 20, 2026, 25 dated June 8, 2026 and one dated October 30, 2026. Its compliance office's 2025 report says 58 letters addressed "misbranded compounded drugs promoted through false or misleading advertising, such as by implying equivalence to FDA-approved products" (FDA, April 2026). Recipients include national platforms, professional practices and med spas.
The FDA's page for telehealth companies, current as of June 15, 2026, lists the claims it treats as false or misleading: "describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA"; saying it "has been FDA-approved or has otherwise been evaluated for safety and effectiveness"; "describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug"; "claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility"; and "using branding on their website that falsely or misleadingly implies the telehealth company is the compounder" (FDA). On February 6, 2026 the FDA added that companies "cannot state compounded drugs use the same active ingredient as the FDA-approved drugs" (FDA).
The letters quote the sellers' own words. Among them: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients" (September 2025); "Compounded Generic Semaglutide is a revolutionary FDA-inspected medication" (September 2025); "Our compounding pharmacies are all FDA approved" and "offers the same results but at a fraction of the cost of brand names" (June 2026); and "FDA-Approved Compounded Medications" and "Well-Studied Compounded Medications" (October 2026). One letter's footnote adds that "Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding." Each letter we read asks for a written response within 15 working days. More on the drugs themselves in compounded tirzepatide and semaglutide.
Whose name goes on the vial
"The appearance on a drug product label of a person's name without qualification is a representation that the named person is the sole manufacturer of the product", and if that person is not the manufacturer the drug is misbranded under 352(a) (21 CFR 201.1(h)(2)). The FDA applied that rule to a telehealth company in February 2026, to an Ohio med spa in June 2026 and to another telehealth company in October 2026, whose labels named the seller, "suggesting" it "is the compounder of those drugs when in fact it is not." In our reading, a clinic that wants its brand on a patient's vial needs the label to say who compounded the drug and in what capacity the clinic appears.
Disclaimers do not rescue a headline claim
The October 30, 2026 letter is direct about it: statements that a product "may not itself be FDA-approved" or that compounded medications are not FDA-approved "do not cure the misleading" overall impression created by claims such as "FDA-Approved Compounded Medications". The FTC's Endorsement Guides use the same test for testimonials: a disclosure, "To be effective", "must alter the net impression of the advertisement so that it is not misleading" (16 CFR 255.2(b)). In our reading, the fix is the claim, not the footnote.
Brief summary and fair balance
Prescription drug advertising has its own rules: a "brief summary" of side effects, contraindications and effectiveness, and a "fair balance" between risk and benefit information (21 U.S.C. 352(n); 21 CFR 202.1). On their face they address ads "issued or caused to be issued by the manufacturer, packer, or distributor". In our reading, whether they apply to a clinic's ads for a compounded drug is unsettled: none of the FDA's compounding marketing letters we read cites them, and the regulation's only compounding passage concerns ads of bulk chemicals to pharmacists. The prudent course is to write every ad as if it must be balanced, because the misleading-by-omission test in 321(n) applies either way.
"Research use only" labels
A label that says "for research use only" or "not for human consumption" does not decide what a product is. The FDA looks at intended use, which "may, for example, be shown by labeling claims, advertising matter, or oral or written statements" (21 CFR 201.128). In an August 24, 2026 warning letter to a peptide seller in Cornelius, North Carolina, the FDA wrote that despite labeling for "laboratory, research, and analytical use" and "not intended for human or veterinary use," "evidence obtained from your website establishes that your products are intended to be drugs for human use." The FDA's GLP-1 page lists warnings to companies selling unapproved GLP-1 drugs "falsely labeled "for research purposes" or "not for human consumption"" (FDA, October 1, 2026). The FDA's 2025 and 2026 advertising letters we found concern compounded GLP-1s; its letters about other peptides are unapproved-drug letters to research-use sellers. More in research-use-only peptides.
The FTC: substantiation, testimonials and reviews
The FTC Act bars "unfair or deceptive acts or practices" (Section 5) and makes it unlawful to disseminate "any false advertisement" likely to induce the purchase of "food, drugs, devices, services, or cosmetics" (Section 12) (15 U.S.C. 45, 52). A "false advertisement" is one "misleading in a material respect", taking account of facts it fails to reveal (15 U.S.C. 55). The FTC's Health Products Compliance Guidance (December 2022) says health claims "require substantiation in the form of competent and reliable scientific evidence", reaches "social media and influencer marketing" and messages "through healthcare practitioners", and warns that "Anyone participating in deceptive marketing is potentially liable" (FTC). It is guidance and "doesn't have the force or effect of law", but it describes how the FTC reads the Act. The FDA has primary responsibility for labeling claims and the FTC "for claims in all forms of advertising".
Two FTC texts govern reviews and testimonials. The Endorsement Guides, revised July 26, 2023, say a testimonial about results will be read as typical, and if the advertiser cannot substantiate that, the ad "should clearly and conspicuously disclose the generally expected performance" (16 CFR 255.2). The Consumer Review rule, effective October 21, 2024, makes it unlawful to write or sell fake reviews or testimonials, to pay for reviews "expressing a particular sentiment, whether positive or negative", to post undisclosed reviews by officers or managers, and to use threats or intimidation to remove a review (16 CFR 465). Because it is a trade regulation rule, a knowing violation can bring civil penalties, now up to $53,088 per violation (16 CFR 1.98(d)).
The closest FTC case is a GLP-1 telehealth firm that settled in 2025. The FTC alleged "unsubstantiated weight loss claims" that members "lose 53 pounds and 23% of their body weight on average", "fake testimonials created by hired individuals, employees, and family members", "deceptive before and after photos of people who were not their customers", and an advertised price that "did not include the cost of the actual GLP-1 drug" (FTC, July 14, 2025). The final order, approved December 3, 2025, "requires competent and reliable evidence to support claims about the average or typical results" and "prohibits manipulation of reviews"; the firm agreed to pay $150,000 (FTC). It is a settlement, not a court finding.
The HHS peptide policy is not a marketing license
HHS's October 30, 2026 draft policy on 503A compounding with six listed peptides sets conditions for compounding, not for advertising, and repeats that "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (91 FR 68526). It is a draft and "is not binding". In our reading, an ad that calls one of those peptides "FDA-approved", "FDA-cleared" or "now legal" raises the same 352(a) and 352(bb) problem as the GLP-1 letters. LegitScript, which certifies telehealth companies for the ad platforms, gives the same caution: "Review labels, marketing, and patient communications to avoid suggesting that enforcement discretion means FDA approval" (LegitScript, November 2, 2026). What the policy covers is in are peptides legal?
Google, Meta and LegitScript
Platform rules are not law, but they decide whether an ad runs. Google allows US online pharmacies and telemedicine providers only if certified by LegitScript (or, for pharmacies, NABP), and it bars promotion of "Non-government approved products that are marketed in a way that implies that they're safe or effective" for treating a disease, and of "Products that imply they're as effective as prescription drugs" (Google Ads). Meta "requires online pharmacies and telehealth providers to be actively certified with LegitScript" and then its own authorization (Meta). LegitScript says violations of its standards include "offering the product, promoting it, or advertising it", and that partnering with a separate entity that dispenses a restricted peptide "doesn't provide a workaround" (LegitScript, September 22, 2026). An ad can pass a platform's review and still be unlawful, and the reverse.
North Carolina
The Medical Board's statement on advertising and publicity (adopted November 1999, amended July 2026) says "advertising or publicity that is deceptive, false, or misleading constitutes unprofessional conduct under the Medical Practice Act" (NCMB). The test is "whether a member of the general public would likely be confused or deceived". Ads "should not contain false claims or misrepresentations of fact", "should not omit material facts", and "licensees should be prepared to substantiate claims made in advertisements." Licensees should avoid advertising "likely to create unjustified medical expectations", "should not post false patient testimonials", and use patient photographs only of "the licensee's own patients" that "demonstrate realistic outcomes."
"Advertising" in the statement includes communication "disseminated by, or at the direction of, a licensee". In our reading, that covers ads a management company or marketing agency runs for a physician practice, so the physician owner answers for them. Who may own a clinic and its management company is in who can own a med spa in North Carolina, and the rest of a clinic's setup in opening a peptide clinic: the legal checklist.
Common questions
Does the FDA regulate ads for compounded drugs?
Yes. Since 2013 a compounded drug is misbranded "If the advertising or promotion of a compounded drug is false or misleading in any particular" (21 U.S.C. 352(bb)). The FDA's 2025 and 2026 warning letters to telehealth companies, clinics and med spas cite it together with 352(a), the false-labeling provision.
Can a clinic call compounded semaglutide "generic Wegovy"?
No. The FDA lists "describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA" as false or misleading, and says compounded drugs "are also not the same as generic drugs, which are FDA-approved." It also objects to saying a compounded drug has the "same active ingredient" as an approved one.
Can our clinic's brand appear on the vial label?
Not alone. Under 21 CFR 201.1(h)(2), a name on a drug label "without qualification" represents that the named person is the sole manufacturer. In 2026 the FDA warned a med spa and telehealth companies whose names on labels suggested they were the compounder when they were not.
Does a disclaimer fix an "FDA-approved" claim?
No. In October 2026 the FDA wrote that disclaimers saying a product "may not itself be FDA-approved" "do not cure the misleading" overall impression of the claim. The FTC applies a similar test: a disclosure must change the net impression of the ad.
Does a "research use only" label protect a peptide seller?
No. The FDA judges intended use from the whole website and the seller's statements (21 CFR 201.128). In an August 2026 letter to a North Carolina peptide seller, it said that despite "research" and "not intended for human" labeling, the website showed the products were "intended to be drugs for human use."
Do FTC rules cover patient testimonials and online reviews?
Yes. The 2024 Consumer Review rule bars fake reviews and testimonials, paying for reviews with a particular sentiment, and undisclosed reviews by officers or managers (16 CFR 465), with civil penalties for knowing violations. The Endorsement Guides require disclosing the generally expected results when a testimonial is not typical (16 CFR 255.2).
Can we advertise compounded GLP-1s or peptides on Google or Meta?
That is platform policy, not law. In the US both require LegitScript certification for telehealth providers and online pharmacies, and Google bars ads implying that non-approved products are safe or effective for a disease. LegitScript says offering, promoting or advertising a restricted peptide breaches its standards.
What does the North Carolina Medical Board say about clinic advertising?
Deceptive, false or misleading advertising "constitutes unprofessional conduct under the Medical Practice Act." Ads should not omit material facts, licensees should be prepared to substantiate their claims, testimonials must not be false, and patient photos should be of the licensee's own patients and show realistic outcomes (statement amended July 2026).
Update log
- November 6, 2026. Published. The statutes (uscode.house.gov, current through Pub. L. 119-124), 21 CFR 201 and 202 and 16 CFR 1, 255 and 465 (eCFR, November 4, 2026), the FDA's telehealth page, releases, compliance report and eight warning letters, the FTC guidance, releases and order, the HHS notice, the Google, Meta and LegitScript pages and the Medical Board statement, all read at the source November 6, 2026. No claim is made that any drug or peptide is safe or effective.
Sources
- 21 U.S.C. 352 (misbranding, including (a), (n) and (bb); current through Pub. L. 119-124)
- 21 U.S.C. 321 (definitions, including (m) labeling and (n) misleading)
- 21 U.S.C. 353a (section 503A, with the 2013 amendment notes)
- 21 CFR 201.1 (name on the label)
- 21 CFR 201.128 (intended use)
- 21 CFR 202.1 (prescription drug advertising)
- FDA, To Telehealth Companies: What to Know When Promoting Compounded Drugs (current as of June 15, 2026)
- FDA, intends to take action against non-FDA-approved GLP-1 drugs (Feb. 6, 2026)
- FDA, warns 30 telehealth companies against illegal marketing of compounded GLP-1s (Mar. 3, 2026)
- FDA CDER Office of Compliance, 2025 Annual Report (April 2026)
- FDA warning letter, Hims & Hers Health, Inc. (Sept. 9, 2025)
- FDA warning letter, The HCG Institute (Sept. 9, 2025)
- FDA warning letter, ybycmeds (Sept. 9, 2025)
- FDA warning letter, MEDVi, LLC (Feb. 20, 2026)
- FDA warning letter, Altru Telehealth (June 8, 2026)
- FDA warning letter, Glow Medispa, LLC dba Mint Med (June 8, 2026)
- FDA warning letter, RonanRx, Inc. (Oct. 30, 2026)
- FDA warning letter, NuScience Peptides LLC, Cornelius, NC (Aug. 24, 2026)
- FDA, concerns with unapproved GLP-1 drugs used for weight loss (current as of Oct. 1, 2026)
- 15 U.S.C. 45, 52 and 55 (FTC Act Sections 5 and 12; false advertisement)
- FTC, Health Products Compliance Guidance (December 2022)
- 16 CFR Part 255, Endorsement Guides (revised July 26, 2023)
- 16 CFR Part 465, Rule on the Use of Consumer Reviews and Testimonials (effective Oct. 21, 2024)
- 16 CFR 1.98 (FTC civil penalty amounts)
- FTC, action against telemedicine firm NextMed (July 14, 2025)
- FTC, final order against NextMed (Dec. 3, 2025)
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Oct. 30, 2026; draft)
- Google Ads, Healthcare and medicines policy
- Meta, Drugs and Pharmaceuticals ad standards
- LegitScript, The Peptide Boom (Sept. 22, 2026)
- LegitScript, HHS peptide compounding policy: what healthcare businesses need to know (Nov. 2, 2026)
- NC Medical Board, Advertising and Publicity (adopted Nov. 1999, amended July 2026)
Related
Reviewing a clinic's or platform's marketing?
DPS Law reviews websites, ads, intake flows, labels and influencer and review programs for clinics, med spas and telehealth companies under federal and North Carolina law. For another state's rules, talk to a lawyer licensed in that state.